Better Biopharma Latest Episode Cell & Gene

1. Developing Antibodies To Block Neuroinflammation With MindImmune's Stevin Zorn, Ph.D. 10/20/2025

   In this episode of "Better Biopharma," host Tyler Menichiello is joined by MindImmune's president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company's lead candidate, MITI-101, a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer's disease.

2. Engineering Bacterial Vector-Based Immunotherapies With OS Therapies' Paul Romness and Robert Petit, Ph.D. 10/7/2025

   In this episode of “Better Biopharma,” host Tyler Menichiello is joined by OS Therapies’ CEO, Paul Romness, and chief medical and scientific officer, Robert Petit, Ph.D. The three discuss the development and manufacturing of the company’s lead asset, OST-HER2, a Listeria-based immunotherapy for osteosarcoma.

3. How J&J Is Tackling Alzheimer's Disease With Fiona Elwood, Ph.D. 9/22/2025

   Fiona Elwood, Ph.D., VP and Neurodegeneration Disease Area Stronghold Leader at Johnson & Johnson, explains the company’s modality-agnostic approach to treating Alzheimer’s disease in this episode of Better Biopharma.

4. CDMO Hunger Games And The State Of Biotech With Siren Biotechnology's Nicole Paulk, Ph.D. 9/9/2025

   Biotech leader Nicole Paulk, Ph.D., joins “Better Biopharma” to discuss Siren Biotechnology’s switch from plasmids to producer cell lines, CGT funding challenges, and the competition that determined which CDMO won Siren’s business.

5. Delivering Biologics To The Brain With Adaptin Bio's Michael Roberts, Ph.D., and Duke University's Mustafa Khasraw, MD 8/26/2025

   In this episode of "Better Biopharma," host Tyler Menichiello is joined by Adaptin Bio's CEO, co-founder, and president, Michael Roberts, Ph.D., and Duke University's Mustafa Khasraw, MD to discuss Adaptin's Brain Bispecific T-cell Engager (BRiTE) platform.

6. Developing An In Vivo CAR-T With Interius BioTherapeutics' Sianny Christanti and Babu Medi, Ph.D. 8/12/2025

   On this episode of Better Biopharma, Interius BioTherapeutics’ Sianny Christanti and Babu Medi, Ph.D., explain how the company is re-engineering a lentiviral vector to enable INT2104, its off-the-shelf, in vivo CAR T-cell therapy. They discuss the vector's design and its manufacturability, as well as the analytical and regulatory challenges of bringing this first-in-human therapy to the clinic.

7. Functional Antibody Screening With Abalone Bio's Richard Yu, Ph.D. 7/29/2025

   In this episode of "Better Biopharma," Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains how the company's functional antibody selection technology (FAST) platform differs from traditional affinity screening.

8. Using Algae To Manufacture Oral Biologics With Lumen Bioscience's Craig Behnke, Ph.D. 7/15/2025

   Lumen Bioscience is putting the farm in biopharma — literally! In this episode of Better Biopharma, Lumen's EVP of production and development, Craig Behnke, Ph.D., explains the company's chlorophyll-powered approach to bioprocessing using photosynthetic cyanobacteria.

9. PILOT: Introducing Better Biopharma 7/15/2025

   How can the biopharmaceutical industry improve? Join Bioprocess Online's Tyler Menichiello as he explores this question through a series of interviews with experts and leaders from across the space. Subscribe for biweekly, in-depth conversations with the brightest minds in biotech to learn how they're moving the needle to make better medicines and optimize manufacturing.